Drug Watch

Drug Watch

The latest on the biggest pipeline moves.

Misconceptions, Pipeline, and Prevention of ID
January 16, 2022

What new treatments are coming to infectious disease? How can they be prevented and what misconceptions are affecting treatment? Learn about this and more in this video with Ted Rosen, MD.

Highlighting the Molluscum Contagiosum Pipeline
January 15, 2022

In this video, Peter Lio, MD, FAAD, expands on his presentation at the 19th annual Winter Clinical Dermatology Conference by diving into molluscum contagiousum treatment and the potential of cantharidin 0.7% (VP-102; Verrica).

Vial Announces Innovative Dermatology CRO
January 12, 2022

Vial launches Vial Dermatology contract research organization (CRO) and highlights how it could improve the speed and quality of clinical trials.

2022 Game Changers: Watch-worthy Drugs, Devices, and Technology
January 11, 2022

The new year promises to be rich with dermatology game changers following a sluggish 2021 for breakthroughs and FDA approvals.

Impact of Itch Sparks New Pipeline Direction
January 07, 2022

Skin sensitivity will be a factor in vehicles for new treatments.

POLL: Which Recent Drug Pipeline Move is Most Exciting?
January 03, 2022

Click here to answer this week's poll.

2021's Breakthroughs & Disappointments
December 23, 2021

The past year gave dermatologists ample cause for both celebration and frustration as they looked forward to new drugs, devices, and technology to optimize patient care. Here, Dermatology Times® editorial advisory board members weigh in on the good, bad, and still-TBD changes that shaped the specialty during 2021.

FDA Accepts NDA Resubmission of VP-102
December 15, 2021

Verrica Pharmaceuticals announced the FDA acceptance of the New Drug Application (NDA) resubmission for VP-102 (Verrica Pharmaceuticals) for the treatment of molluscum contagiosum.

FDA Grants Priority Review to Spesolimab
December 15, 2021

The FDA grants Priority Review for spesolimab (BI655130; Boehringer Ingelheim) as a treatment for generalized pustular psoriasis.

Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis
December 15, 2021

The FDA approves upadacitinib (Rinvoq; AbbVie) for the treatment of adult patients with active psoriatic arthritis.